Science ImmunologyImmunologyPeer-reviewed journal article
In vivo reprogramming of cytotoxic effector CD8+ T cells via fractalkine-conjugated mRNA-LNP
Angela R. CorriganiD, Shin Foong NgiowiD, Maura StatzuiD, Amie AlbertusiD, María Betina PampenaiD, Jayme M.L. NordiniD, Stephen D. CarroiD, Justin L. HarperiD, Rachelle L. StammeniD, Jennifer WoodiD, Houping NiiD, Justin SuiD, Marziyeh HajialyaniiD, Vladimir V. ShuvaeviD, Víctor AlcaldeiD, Mohammed-Alkhatim A. AliiD, Jacob T. HamiltoniD, Rajesvaran Ramalingam, Vincent H. WuiD, Mirko PaiardiniiD, Drew WeissmaniD, E. John WherryiD, Edward F. KreideriD, Michael R. BettsiD
Abstract
Selective in vivo reprogramming of cytotoxic effector CD8+ T (Teff) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA-LNP) can specifically target and deliver mRNA to CX3CR1+ Teff cells in vitro and in vivo. In mice, fractalkine-conjugated LNP target up to 90% of blood and splenic Teff cells, and delivery of IL-2-encoding mRNA to Teff cells enables robust exogenous IL-2 secretion. In rhesus macaques, fractalkine-conjugated mRNA-LNP target up to [~]100% of peripheral blood Teff cells and delivery of CD62L-mRNA enables transient CD62L expression. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA-LNP for effective and efficient transient in vivo modification of Teff cells.
- organism: mouse
- organism: rat
- assay: multiome
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: drug response / drug discovery
- research focus: perturbation response prediction
- approach: experimental assay
- Citations
- 1
- FWCI
- 2.05
- Field percentile
- top 14%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An inherent T cell-activating mRNA delivery platform for in vivo CAR T generation
Qiannan Cao, Yufei Yao, … Huayu Tian·bioRxiv·Nov 19, 2025
- The type I IFN-IL-27 axis promotes mRNA vaccine-induced CD8+ T cell responses
Anthony T. Phan, Emily Aunins, … Christopher A. Hunter·bioRxiv·Jan 16, 2025
- Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering
Jianhao Zeng, Tyler Ellis Papp, … Hamideh Parhiz·Journal of Controlled ReleasePeer-reviewed·May 21, 2026
- Langerhans Cell-targeted mRNA Delivery: A Strategy for Dose-Sparing and Enhanced Anti-Tumor Immunity
Klara Klein, Litty Johnson, … Florian Sparber·Journal of Investigative DermatologyPeer-reviewed·Apr 7, 2026
- Dual-targeted nanoparticles enable the ex vivo generation of cytotoxic and phagocytic CAR effector cells
Jisu Hong, Jinwoong Lim, … Dohyun Han·bioRxiv·Sep 22, 2026
- Effective targeting of CD19 positive primary B-ALL cells using CAR-NK cells generated with mRNA-LNPs
Hossein Salehi-Shadkami, Mosslim Sedghi, … Vahid Khoddami·Current Research in Translational MedicinePeer-reviewed·Dec 17, 2025